Ocular Therapeutix (OCUL) Other financing activities (2013 - 2026)

Ocular Therapeutix's Other financing activities history runs 14 years deep, the most recent figure standing at $294000.0 for Q1 2026.

• On a quarterly basis, Other financing activities fell 92.97% year-over-year to $294000.0 in Q1 2026; TTM through Mar 2026 was -$2.3 million, a 99.23% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, down 89.2% from the prior year.
• Other financing activities eased to $294000.0 in Q1 2026 per OCUL's latest filing, from $879000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $316.4 million in Q1 2024 and bottomed at -$309.8 million in Q2 2024.
• The 5-year median for Other financing activities is $340000.0 (2023), against an average of $1.5 million.
• Biggest YoY gain for Other financing activities was 405480.77% in 2024; the steepest drop was 91211.47% in 2024.
• Year by year, Other financing activities stood at $32000.0 in 2022, then soared by 14793.75% to $4.8 million in 2023, then surged by 198.97% to $14.2 million in 2024, then plunged by 93.83% to $879000.0 in 2025, then plunged by 66.55% to $294000.0 in 2026.
• Per Business Quant, the three latest OCUL Other financing activities figures stand at $294000.0 (Q1 2026), $879000.0 (Q4 2025), and -$6.5 million (Q3 2025).